Date: 2013-05-28
Type of information: R&D agreement
Compound: programme of vector construction
Company: Cobra Biologics (Sweden) Recopharma (Sweden)
Therapeutic area: Technology - Services
Type agreement: R&D
Action mechanism:
Disease:
Details: * On May 28, 2013, Cobra Biologics and Recopharma have entered agreement to utilise Cobra’s Cell Line Development Service- MaxXpress. Cobra Biologics will apply its cost-effective maxXpress platform service to deliver a programme of vector construction using the UCOE technology, transfectant pool generation, and supply, purification and protein characterisation. The service allows Recopharma to form a quick and reliable assessment on the specific expertise of Cobra’s cell line development and analytical scientist teams.
Recopharma has developed a unique technology that uses mucins, naturally occurring proteins produced by epithelial tissues with many potential applications. The FC fused mucins will provide a natural alternative to ocular lubricants and tear substitutes that are at present available and set to be used as a treatment and prophylactic that tackles viral conjunctivitis.
Financial terms:
Latest news:
